2026年6月22日,国家药品监督管理局消息,百利天恒自主研发的EGFR×HER3双抗ADC药物伦康依隆妥单抗、恺兴生命科技(上海)有限公司的舒瑞基奥仑赛注射液、智翔金泰的斯乐韦米单抗在国内获批上市。 其中,伦康依隆妥单抗用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌的成人患者。本次是伦康依隆妥单抗的全球首批,从上市申请获得受理到正式获批仅历时7个月即获批...
Source Link2026年6月22日,国家药品监督管理局消息,百利天恒自主研发的EGFR×HER3双抗ADC药物伦康依隆妥单抗、恺兴生命科技(上海)有限公司的舒瑞基奥仑赛注射液、智翔金泰的斯乐韦米单抗在国内获批上市。 其中,伦康依隆妥单抗用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌的成人患者。本次是伦康依隆妥单抗的全球首批,从上市申请获得受理到正式获批仅历时7个月即获批...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.